Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRI NASDAQ:INDV TSE:ITH NASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRIGRI Bio$2.03-5.6%$2.42$2.03▼$80.36$3.81M-1.2241,390 shs21,569 shsINDVIndivior$36.76-2.8%$32.93$11.04▼$41.00$4.61B0.92.35 million shs1.82 million shsITHInternational Tower Hill MinesC$3.39-6.9%C$3.41C$0.91▼C$4.94C$886.95M2.05896286,047 shs81,614 shsSOPHSOPHiA GENETICS$4.63-2.3%$4.88$2.59▼$5.70$324.62M1.01111,297 shs46,184 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRIGRI Bio-5.58%-8.76%-17.81%-12.12%-95.07%INDVIndivior-2.83%-6.94%+13.04%+6.30%+233.27%ITHInternational Tower Hill Mines-6.87%-3.42%-2.59%+0.30%+264.52%SOPHSOPHiA GENETICS-2.32%-10.10%-8.68%-2.32%+50.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRIGRI Bio$2.03-5.6%$2.42$2.03▼$80.36$3.81M-1.2241,390 shs21,569 shsINDVIndivior$36.76-2.8%$32.93$11.04▼$41.00$4.61B0.92.35 million shs1.82 million shsITHInternational Tower Hill MinesC$3.39-6.9%C$3.41C$0.91▼C$4.94C$886.95M2.05896286,047 shs81,614 shsSOPHSOPHiA GENETICS$4.63-2.3%$4.88$2.59▼$5.70$324.62M1.01111,297 shs46,184 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRIGRI Bio-5.58%-8.76%-17.81%-12.12%-95.07%INDVIndivior-2.83%-6.94%+13.04%+6.30%+233.27%ITHInternational Tower Hill Mines-6.87%-3.42%-2.59%+0.30%+264.52%SOPHSOPHiA GENETICS-2.32%-10.10%-8.68%-2.32%+50.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRIGRI Bio 2.33Hold$1,008.0049,555.17% UpsideINDVIndivior 3.00Buy$39.337.00% UpsideITHInternational Tower Hill Mines 0.00N/AN/AN/ASOPHSOPHiA GENETICS 2.33Hold$7.5061.99% UpsideCurrent Analyst Ratings BreakdownLatest GRI, SOPH, ITH, and INDV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/6/2026SOPHSOPHiA GENETICS BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.004/21/2026GRIGRI Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026SOPHSOPHiA GENETICS Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026SOPHSOPHiA GENETICS BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $8.003/17/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)3/16/2026INDVIndivior Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/3/2026SOPHSOPHiA GENETICS BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.003/2/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Buy (B-)(Data available from 5/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRIGRI BioN/AN/AN/AN/A$5.95 per shareN/AINDVIndivior$1.29B3.47$2.64 per share13.91($1.18) per share-31.15ITHInternational Tower Hill MinesN/AN/AC$0.15 per share22.50C$0.69 per shareN/ASOPHSOPHiA GENETICS$81.18M3.91N/AN/A$0.67 per share6.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRIGRI Bio-$11.96M-$235.02N/AN/AN/AN/A-199.52%-143.23%5/21/2026 (Estimated)INDVIndivior$210M$1.9518.859.99N/A19.44%-219.26%29.40%7/30/2026 (Estimated)ITHInternational Tower Hill Mines-C$2.36M-C$0.01N/AN/AN/AN/A-2.04%-3.65%N/ASOPHSOPHiA GENETICS-$79M-$0.52N/AN/AN/A-44.48%-62.74%-21.85%8/4/2026 (Estimated)Latest GRI, SOPH, ITH, and INDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026GRIGRI Bio-$3.74N/AN/AN/AN/AN/A5/13/2026Q1 2026GRIGRI Bio-$0.91-$1.61-$0.70-$1.61N/AN/A5/5/2026Q1 2026SOPHSOPHiA GENETICS-$0.2325-$0.27-$0.0375-$0.27$20.40 million$21.69 million4/30/2026Q1 2026INDVIndivior$0.64$0.96+$0.32$3.45$272.84 million$317.00 million3/31/2026Q1 2026INDVIndiviorN/A$0.96N/A$3.45N/A$317.00 million3/11/2026Q4 2025ITHInternational Tower Hill MinesN/A-C$0.02N/AN/AN/AN/A3/3/2026Q4 2025SOPHSOPHiA GENETICS-$0.20-$0.28-$0.08-$0.28$21.20 million$21.71 million2/27/2026Q4 2025INDVIndivior$0.65$0.82+$0.17$3.95$305.62 million$358.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGRIGRI BioN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AITHInternational Tower Hill MinesN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRIGRI BioN/A14.203.25INDVIndiviorN/A0.860.66ITHInternational Tower Hill MinesN/A238.0330.48SOPHSOPHiA GENETICS1.052.061.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRIGRI Bio33.95%INDVIndivior60.33%ITHInternational Tower Hill Mines8.85%SOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipGRIGRI Bio8.73%INDVIndivior0.74%ITHInternational Tower Hill Mines0.51%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRIGRI Bio11.77 million1.32 millionNot OptionableINDVIndivior1,051121.92 million121.02 millionNot OptionableITHInternational Tower Hill Mines220261.64 millionN/ANot OptionableSOPHSOPHiA GENETICS52068.49 million65.14 millionNot OptionableGRI, ITH, SOPH, and INDV HeadlinesRecent News About These CompaniesSynnovis and SOPHiA GENETICS partner to bring blood-based cancer testing to patients across UKMay 15 at 8:13 PM | pharmabiz.comPSynnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.May 13 at 5:00 AM | prnewswire.comAlternate Health (OTCMKTS:AHGIF) and SOPHiA GENETICS (NASDAQ:SOPH) Head-To-Head ReviewMay 12, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), SOPHiA GENETICS (SOPH) and Solventum Corporation (SOLV)May 9, 2026 | theglobeandmail.comSOPHiA GENETICS (NASDAQ:SOPH) Given Buy Rating at BTIG ResearchMay 7, 2026 | americanbankingnews.comSOPHiA GENETICS (NASDAQ:SOPH) Earns Buy Rating from BTIG ResearchMay 6, 2026 | marketbeat.comCritical Comparison: SOPHiA GENETICS (NASDAQ:SOPH) vs. MDxHealth (NASDAQ:MDXH)May 6, 2026 | americanbankingnews.comSOPHiA Genetics (SOPH) Q1 2026 Earnings TranscriptMay 5, 2026 | finance.yahoo.comSOPHiA GENETICS Q1 Earnings Call HighlightsMay 5, 2026 | marketbeat.comSOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comSOPHiA GENETICS (NASDAQ:SOPH) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPSMay 5, 2026 | marketbeat.comBTIG Raises its Price Target on SOPHiA GENETICS (SOPH) to $8May 5, 2026 | finance.yahoo.comSOPHiA GENETICS Reports First Quarter 2026 ResultsMay 5, 2026 | prnewswire.comUncovering MTAP deletions in precision oncology researchApril 30, 2026 | labroots.comLSOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $24,100.00 in StockApril 28, 2026 | marketbeat.comShort Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Drops By 31.0%April 28, 2026 | marketbeat.comSOPHiA GENETICS (SOPH) Projected to Post Earnings on TuesdayApril 28, 2026 | marketbeat.comHow The SOPHiA GENETICS (NasdaqGS:SOPH) Narrative Is Shifting With New Fair Value TargetsApril 26, 2026 | finance.yahoo.comSOPHiA GENETICS SAApril 23, 2026 | edition.cnn.comInsider Selling: SOPHiA GENETICS (NASDAQ:SOPH) CEO Sells 4,486 Shares of StockApril 21, 2026 | marketbeat.comSOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026April 21, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesApple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026Alphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 20265 Stocks to Buy in May Before the Next AI Surge HitsBy Thomas Hughes | May 1, 2026The $880M Bet to Survive Real Estate's ResetBy Jeffrey Neal Johnson | April 28, 2026Pipelines and Automation: 2 Energy Plays Built for Any Oil PriceBy Chris Markoch | April 26, 2026GRI, ITH, SOPH, and INDV Company DescriptionsGRI Bio NASDAQ:GRI$2.03 -0.12 (-5.58%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$2.07 +0.04 (+1.87%) As of 05/15/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Indivior NASDAQ:INDV$36.76 -1.07 (-2.83%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$36.35 -0.41 (-1.10%) As of 05/15/2026 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.International Tower Hill Mines TSE:ITHC$3.39 -0.25 (-6.87%) As of 05/15/2026 04:00 PM EasternInternational Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an advanced stage exploration project namely the Livengood Gold Project. It is located approximately 70 miles northwest of Fairbanks, Alaska in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska mental health trust, a number of smaller private mineral leases, Alaska state mining claims purchased or located by the company and patented ground held by the company.SOPHiA GENETICS NASDAQ:SOPH$4.63 -0.11 (-2.32%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$4.62 -0.01 (-0.32%) As of 05/15/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
